Related Experiment Video
Updated: Dec 13, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
9.0K
Circulating tumor DNA in neuroblastoma.
Meng Wei1, Mujie Ye1, Kuiran Dong1
1Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China.
Pediatric Blood & Cancer
|July 31, 2020
Summary
Detecting circulating tumor DNA (ctDNA) in blood offers a less invasive way to find diagnostic and prognostic markers for aggressive neuroblastoma (NB). This analysis aids in treatment guidance and improving patient outcomes.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Neuroblastoma (NB) is an aggressive tumor derived from the sympathetic nervous system.
- There is a need for less invasive diagnostic and prognostic markers for NB.
- Circulating tumor DNA (ctDNA) analysis in peripheral blood offers a non-surgical approach to obtain tumor genetic information.
Purpose of the Study:
- To explore the clinical value of ctDNA analysis in neuroblastoma.
- To assess ctDNA's role in diagnosis, risk stratification, treatment monitoring, and survival prediction.
Main Methods:
- Analysis of ctDNA in peripheral blood.
- Identification of genetic alterations, chromosomal variations, and hypermethylation within plasma DNA.
- Application of advanced technologies like genome sequencing and droplet digital PCR.
Main Results:
- ctDNA analysis provides genetic information from multiple tumor sites.
- Detection of genetic alterations, chromosomal variations, and hypermethylation in plasma DNA.
- ctDNA analysis has significant clinical value in NB management.
Conclusions:
- ctDNA detection is a promising tool for neuroblastoma management.
- It can guide therapeutic schedules, improve quality of life, and enhance patient prognosis.
- Less invasive procedures like ctDNA analysis are crucial for aggressive NB research.
